Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 22:16:336.
doi: 10.1186/s12879-016-1672-2.

HBV/HIV co-infection and APOBEC3G polymorphisms in a population from Burkina Faso

Tegwinde Rebeca Compaore  1 , Birama Diarra  1 , Maleki Assih  1 , Dorcas Obiri-Yeboah  2 , Serge Theophile Soubeiga  1 , Abdoul Karim Ouattara  1 , Damehan Tchelougou  1 , Cyrille Bisseye  1 , Didier Romuald Bakouan  3 , Issaka Pierre Compaore  1 , Augustine Dembele  3 , Wendkuuni Florencia Djigma  1 , Jacques Simpore  4
Affiliations

HBV/HIV co-infection and APOBEC3G polymorphisms in a population from Burkina Faso

Tegwinde Rebeca Compaore et al. BMC Infect Dis. .

Abstract

Background: Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G) is a potent host defense factor, which interferes with HIV-1 and HBV. Our study had three objectives, to screen a population of HIV-1 infected and uninfected patients in Burkina Faso for HBV, to screen the population for APOBEC3G variants rs6001417, rs8177832, and rs35228531 previously described, and to analyze the effect of these three variants and their haplotypes on HIV-1/HBV co-infection in Burkina Faso.

Methods: HBV detection was performed on samples from HIV-1 infected and uninfected subjects using rapid detection tests and real-time PCR. APOBEC3 genotyping was done by the TaqMan allelic discrimination method. Fisher Exact test, Odds ratio (OR), confidence intervals (CI) at 95 %, Linkage disequilibrium (LD) summary statistics and haplotype frequencies were calculated.

Results: The prevalence of HBV was 56.7 % among HIV-1 positive patients of our study while it was about 12.8 % among HIV-1 seronegative subjects. Genotype E was the genotype of HBV present in our hepatitis B positive samples. Minor allele frequencies of rs6001417, rs8177832, and rs35228531 were higher in seronegative subjects. The T minor allele of variant rs35228531 was protective against HIV-1/HBV co-infection with OR = 0.61, 95 % CI (0.42-0.90), p = 0.013. There was also an association between the GGT haplotype and protection against HIV-1/HBV co-infection, OR = 0.57, 95 % CI (0.33-0.99), p = 0.050. The other haplotypes present in the population were not statistically significant. There minor allele T of the rs35228531 was protective against HIV mono-infection OR = 0.53, 95 % CI (0.3-0.93), P = 0.030. But there was no effect of protection against HBV mono-infection.

Conclusion: APOBEC3G through its variants rs6001417, rs8177832, and rs35228531, in this study interferes with HIV-1/HBV co-infection could be due the HIV-1 mono-infection in a population from Burkina Faso.

Keywords: APOBEC3G variants; Burkina Faso; HIV-1/HBV co-infection; Real time PCR.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization Factsheet: Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 6 June 2016.
    1. Tao I, Compaore TR, Diarra B, Djigma F, Zohoncon TM, Assih M, et al. Seroepidemiology of hepatitis B and C viruses in the general population of burkina faso. Hepat Res Treat. 2014;2014:781843. - PMC - PubMed
    1. World Health Organization Factsheet: HIV/AIDS. http://www.who.int/mediacentre/factsheets/fs360/en/. Accessed 6 June 2016.
    1. Antonucci G, Goletti D, Lanini S, Girardi E, Loiacono O. HIV/HCV co-infection: putting the pieces of the puzzle together. Cell Death Differ. 2003;10(Suppl 1):S25–6. doi: 10.1038/sj.cdd.4401164. - DOI - PubMed
    1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(1 Suppl):S6–9. doi: 10.1016/j.jhep.2005.11.004. - DOI - PubMed

MeSH terms

Substances